Clinical Trial Update: Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating irinotecan liposome injection as a second-line regimen for small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Irinotecan liposome injection (irinotecan liposome injection)

Snippet

Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. | Conditions: Small Cell Lung Cancer (SCLC) | Phase 2 | Status: COMPLETED